SG11202108770TA - Combination therapy for treatment of b-cell malignancies - Google Patents
Combination therapy for treatment of b-cell malignanciesInfo
- Publication number
- SG11202108770TA SG11202108770TA SG11202108770TA SG11202108770TA SG11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA SG 11202108770T A SG11202108770T A SG 11202108770TA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- combination therapy
- cell malignancies
- malignancies
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962806148P | 2019-02-15 | 2019-02-15 | |
PCT/IB2020/051270 WO2020165861A1 (en) | 2019-02-15 | 2020-02-14 | Combination therapy for treatment of b-cell malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108770TA true SG11202108770TA (en) | 2021-09-29 |
Family
ID=69740437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108770TA SG11202108770TA (en) | 2019-02-15 | 2020-02-14 | Combination therapy for treatment of b-cell malignancies |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200262925A1 (en) |
EP (1) | EP3923945A1 (en) |
JP (1) | JP2022520429A (en) |
KR (1) | KR20210129111A (en) |
CN (1) | CN113766918A (en) |
AU (1) | AU2020222359A1 (en) |
CA (1) | CA3129593A1 (en) |
EA (1) | EA202192256A1 (en) |
IL (1) | IL285458A (en) |
JO (1) | JOP20210225A1 (en) |
MA (1) | MA54941A (en) |
MX (1) | MX2021009821A (en) |
SG (1) | SG11202108770TA (en) |
WO (1) | WO2020165861A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
KR20160066554A (en) * | 2013-10-25 | 2016-06-10 | 파마싸이클릭스 엘엘씨 | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
RS63364B1 (en) * | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
WO2016128912A1 (en) * | 2015-02-12 | 2016-08-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor |
JP6944936B2 (en) * | 2015-12-04 | 2021-10-06 | ポートラ ファーマシューティカルズ, インコーポレイテッド | Serduratinib for treating blood cancer |
TWI739887B (en) * | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | Treatment cancers using a combination comprising btk inhibitors |
-
2020
- 2020-02-14 SG SG11202108770TA patent/SG11202108770TA/en unknown
- 2020-02-14 CA CA3129593A patent/CA3129593A1/en active Pending
- 2020-02-14 EA EA202192256A patent/EA202192256A1/en unknown
- 2020-02-14 KR KR1020217029364A patent/KR20210129111A/en unknown
- 2020-02-14 CN CN202080029634.3A patent/CN113766918A/en active Pending
- 2020-02-14 MX MX2021009821A patent/MX2021009821A/en unknown
- 2020-02-14 JO JOP/2021/0225A patent/JOP20210225A1/en unknown
- 2020-02-14 JP JP2021547345A patent/JP2022520429A/en active Pending
- 2020-02-14 MA MA054941A patent/MA54941A/en unknown
- 2020-02-14 EP EP20708643.0A patent/EP3923945A1/en not_active Withdrawn
- 2020-02-14 US US16/791,217 patent/US20200262925A1/en active Pending
- 2020-02-14 AU AU2020222359A patent/AU2020222359A1/en active Pending
- 2020-02-14 WO PCT/IB2020/051270 patent/WO2020165861A1/en unknown
-
2021
- 2021-08-09 IL IL285458A patent/IL285458A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210129111A (en) | 2021-10-27 |
EP3923945A1 (en) | 2021-12-22 |
CN113766918A (en) | 2021-12-07 |
MX2021009821A (en) | 2021-11-12 |
IL285458A (en) | 2021-09-30 |
JOP20210225A1 (en) | 2023-01-30 |
WO2020165861A1 (en) | 2020-08-20 |
EA202192256A1 (en) | 2021-10-27 |
MA54941A (en) | 2021-12-22 |
AU2020222359A1 (en) | 2021-09-02 |
US20200262925A1 (en) | 2020-08-20 |
JP2022520429A (en) | 2022-03-30 |
CA3129593A1 (en) | 2020-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281256A (en) | Combination therapy for the treatment of triple-negative breast cancer | |
IL276398A (en) | Combination therapy for the treatment of mastocytosis | |
IL267795A (en) | Combination therapy for the treatment of cancer | |
IL292810A (en) | Therapeutic compounds and methods of use | |
ZA202206743B (en) | Therapy for the treatment of cancer | |
IL280337A (en) | Lag-3 combination therapy for the treatment of cancer | |
IL281845A (en) | Combination therapy for the treatment of cancer | |
IL285155A (en) | Metal chelator combination therapy for the treatment of cancer | |
SG11202011117VA (en) | Treatment of cancer | |
EP4010081A4 (en) | Combination therapy for treatment of cancer | |
IL284162A (en) | Combination therapy for the treatment of cancer | |
IL282643A (en) | Combination therapy for treatment of hematological diseases | |
IL279591A (en) | Methods of treating cancer using combination therapy | |
GB2587172B (en) | Pyronaridine or pharmaceutically acceptable salts thereof for the treatment of cancer | |
IL266993A (en) | Combination therapy for the treatment of cancer | |
IL281997A (en) | Combination therapy for the treatment of uveal melanoma | |
GB201800736D0 (en) | Combination therapy for treatment of leukemia | |
IL281281A (en) | Combination therapy for the treatment of prostate cancer | |
EP4110344A4 (en) | Use of thyromimetics for the treatment of cancer | |
EP4037761C0 (en) | Device for radiotherapy treatment of cancer patients | |
IL289201A (en) | Compounds for treatment of cancer | |
IL286353A (en) | Combinations of iadademstat for cancer therapy | |
IL285458A (en) | Combination therapy for treatment of b-cell malignancies | |
IL263905A (en) | Combination therapy of cancer | |
IL253642A0 (en) | Combination therapy for the treatment of cancer |